B. Mathers, Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review, The Lancet, vol.372, issue.9651, 2008.
DOI : 10.1016/S0140-6736(08)61311-2

P. Nelson, The epidemiology of viral hepatitis among people who inject drugs: Results of global systematic reviews, Lancet, 2011.

E. Roy, Hepatitis C virus incidence among young street-involved IDUs in relation to injection experience. Drug Alcohol Depend, 2009.

C. Acejias and T. Rhodes, Global estimates of prevalence of HCV infection among injecting drug users, International Journal of Drug Policy, vol.18, issue.5, 2007.
DOI : 10.1016/j.drugpo.2007.04.004

J. Rockstroph, HIV and hepatitis C virus co-infection, Lancet Infect Dis, 2004.

M. Jauffret-roustide, Estimation de la séroprévalence du VIH et de l'hépatite C chez les usagers de drogues en France ? premiers résultats de l'enquête ANRS- COQUELICOT, pp.39-40, 2011.

J. Grebely, Recommandations pour la prise en charge de l'infection par le virus de

B. Zanini, Addicts with chronic hepatitis C: Difficult to reach, manage or treat? World Journal of gastro-enterology, 2013.

N. Papadopoulos, Frequency and predictors of no treatment in anti-hepatitis C virus-positive patients at tertiary liver centers in Greece, European Journal of Gastroenterology & Hepatology, vol.25, issue.5, 2013.
DOI : 10.1097/MEG.0b013e32835cb5c0

A. Graber, Etat des lieux de la prise en charge de l'hépatite C chronique chez les patients migrants en situation de précarité au centre hospitalier de Chambéry. Human health and pathology, 2014.

S. Schaeffer and M. Et-khalili, Reasons for HCV non-treatment in underserved African Americans: Implications for treatment with new therapeutics, Ann. Hepatol, 2015.

G. J. Dore, Elbasvir???Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy, Annals of Internal Medicine, 2016.
DOI : 10.7326/M16-0816

A. Litwin, The PREVAIL Study: intensive models of HCV care for people who inject drugs, Journal of Hepatology, vol.66, issue.1, 2017.
DOI : 10.1016/S0168-8278(17)30406-3

I. Kurelac, Intravenous Drug Users Can Achieve a High Sustained Virological Response Rate: experience From Croatian Reference Center for Viral Hepatitis. Hepatitis monthly, 2011.
DOI : 10.5812/kowsar.1735143x.779

URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3282032/pdf

A. Sundus, Hepatitis patients lost to follow-up at a liver centre in a tertiary care hospital of Karachi, Pakistan ? a cross-sectional descriptive study, 2013.

G. Unal, Les patients perdus de vue en région Haute Normandie en 2013, COREVIH Haute Normandie

E. Lanoy, How does loss to follow-up influence cohort findings on HIV infection? A joint analysis of the French hospital database on HIV, Mortalit?? 2000 survey and death certificates, HIV Medicine, vol.10, issue.4, 2009.
DOI : 10.1111/j.1468-1293.2008.00678.x

R. Jaries, Description du profil des sujets diagnostiqués séropositifs pour le VIH et de leur devenir durant la première année suivant le diagnostic dans l'Ouest Guyanais en Guyane, 2014.

M. Brinkhof, Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries, 2008.
URL : https://hal.archives-ouvertes.fr/inserm-00182959

. Mclaren, Barriers to Hepatitis C Virus Treatment in a Canadian HIV-Hepatitis C Virus Coinfection Tertiary Care Clinic, Canadian Journal of Gastroenterology, vol.22, issue.2, 2008.
DOI : 10.1155/2008/949582

J. Fuertes, The physician?patient working alliance. Patient education and counselling, 2007.
DOI : 10.1016/j.pec.2006.09.013

W. R. Miller, S. Et, and . Rollnick, L'entretien motivationnel, aider la personne à engager le changement

M. Jauffret-roustide, Représentations du traitement de l'hépatite C chez les usagers de drogues, Enquête InVS-ANRS Coquelicot, 2004.

L. Michel, Insufficient access to harm reduction measures in prisons in 5 countries (PRIDE Europe): a shared European public health concern, BMC Public Health, vol.106, issue.11, 2015.
DOI : 10.1111/j.1360-0443.2011.03515.x

URL : https://hal.archives-ouvertes.fr/inserm-01264470

C. Semaille, Prevalence of human immunodeficiency virus and hepatitis C virus 53, 2004.

C. Van-den-berg, Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users, Addiction, vol.361, issue.9, 2007.
DOI : 10.1111/j.1360-0443.2007.01912.x

A. Stornes, Assessment and management of HCV infection. It's your liver: peer to peer HCV testing and education, 2016.

M. Cornberg, A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel, Liver International, vol.86, issue.(S, 2011.
DOI : 10.1053/j.gastro.2009.02.006

S. Hutchinson, Epidemiology & importance of monitoring. EASL-The International Liver Congress 2014, 49th Annual Meeting of the European Association for the Study of the Liver, 2014.

E. Avril, Prévalence de la fibrose hépatique chez les usagers de drogues fréquentant les Caarud et Csapa d'Île-de-France

S. Creusillet, Un parcours de santé " bas seuil " pour atteindre le foyer viral de l'hépatite C. Le courrier des addictions, 2016.

A. Hill, Significant reductions in costs of generic production of sofosbuvir and

A. Cousien, Hepatitis C treatment as prevention of viral transmission and liver-related morbidity in persons who inject drugs, Hepatology, vol.8, issue.Suppl 1, 2016.
DOI : 10.1371/journal.pone.0078286

L. Degenhardt, Estimating the burden of disease attributable to injecting drug use as a risk factor for HIV, hepatitis C, and hepatitis B: findings from the Global Burden of Disease Study 2013, The Lancet Infectious Diseases, vol.16, issue.12, 2016.
DOI : 10.1016/S1473-3099(16)30325-5

J. Reimer, Psychoeducation Improves Hepatitis C Virus Treatment During Opioid Substitution Therapy: A Controlled, Prospective Multicenter Trial, Clinical Infectious Diseases, vol.57, issue.suppl_2
DOI : 10.1093/cid/cit307

URL : https://academic.oup.com/cid/article-pdf/57/suppl_2/S97/20912419/cit307.pdf

V. Annexe, Texte pour l'appel du médecin traitant Au secrétariat : Bonjour, je suis Hélène Van Elslande

. Au, . Bonjour, C. Suis-hélène-van-elslande, and . De-rouen, Je fais ma thèse sur les patients perdus de vue de l'hépatite C